EA201991729A1 - ANTIBODIES TO TGF-BETA AND THEIR APPLICATION - Google Patents
ANTIBODIES TO TGF-BETA AND THEIR APPLICATIONInfo
- Publication number
- EA201991729A1 EA201991729A1 EA201991729A EA201991729A EA201991729A1 EA 201991729 A1 EA201991729 A1 EA 201991729A1 EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A1 EA201991729 A1 EA 201991729A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tgf
- antibodies
- beta
- application
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
В настоящем изобретении предусмотрено улучшенное панспецифичное антитело к TGF-β для лечения состояний, опосредованных TGF-β, в том числе аутоиммунных заболеваний, фиброзных состояний и форм рака. Также предусмотрены способы и пути применения антитела в сочетании с другими иммуномодулирующими средствами, такими как антитело к PD-1.The present invention provides an improved pan-specific antibody to TGF-β for the treatment of conditions mediated by TGF-β, including autoimmune diseases, fibrotic conditions and forms of cancer. Also provided are methods and routes for using the antibody in combination with other immunomodulatory agents, such as an anti-PD-1 antibody.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305061 | 2017-01-20 | ||
PCT/IB2018/000088 WO2018134681A1 (en) | 2017-01-20 | 2018-01-19 | Anti-tgf-beta antibodies and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991729A1 true EA201991729A1 (en) | 2019-12-30 |
Family
ID=58018036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991729A EA201991729A1 (en) | 2017-01-20 | 2018-01-19 | ANTIBODIES TO TGF-BETA AND THEIR APPLICATION |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3571227A1 (en) |
EA (1) | EA201991729A1 (en) |
WO (1) | WO2018134681A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
TW202019962A (en) | 2018-07-10 | 2020-06-01 | 法商賽諾菲公司 | Combination therapies targeting cd38 and tgf-beta |
PE20220279A1 (en) | 2019-01-30 | 2022-02-25 | Scholar Rock Inc | SPECIFIC INHIBITORS OF THE LTBP COMPLEX OF TGF BETA AND USES THEREOF |
IL294650A (en) | 2020-01-11 | 2022-09-01 | Scholar Rock Inc | Tgfbeta inhibitors and use thereof |
US20230050148A1 (en) | 2020-01-11 | 2023-02-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
TW202304979A (en) * | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060286105A1 (en) | 2003-04-30 | 2006-12-21 | Steven Ledbetter | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
CN101163502A (en) | 2005-02-08 | 2008-04-16 | 根茨美公司 | Antibodies to tgf-beta |
RU2625034C2 (en) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Antibodies and other molecules binding b7-h1 and pd-1 |
ES2763869T3 (en) * | 2013-03-20 | 2020-06-01 | Genzyme Corp | Methods of treating osteogenesis imperfecta |
CN107011441B (en) | 2013-09-13 | 2020-12-01 | 百济神州(广州)生物科技有限公司 | anti-PD 1 antibodies and their use as therapeutic and diagnostic agents |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
MX2017004810A (en) * | 2014-10-14 | 2017-10-16 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof. |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
ES2820768T3 (en) * | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Cancer treatment using TGF-beta and PD-1 inhibitors |
-
2018
- 2018-01-19 EA EA201991729A patent/EA201991729A1/en unknown
- 2018-01-19 EP EP18711394.9A patent/EP3571227A1/en active Pending
- 2018-01-19 WO PCT/IB2018/000088 patent/WO2018134681A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018134681A8 (en) | 2019-10-10 |
EP3571227A1 (en) | 2019-11-27 |
WO2018134681A1 (en) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991729A1 (en) | ANTIBODIES TO TGF-BETA AND THEIR APPLICATION | |
EA201891732A1 (en) | BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR | |
MD3303379T2 (en) | Tigit-binding agents and uses thereof | |
EA201891983A8 (en) | COMBINED THERAPY BY ANTIBODIES TO CD73 | |
EA201990208A1 (en) | CHIMER ANTIGENIC RECEPTORS AIMED AT BCMA AND WAYS OF THEIR APPLICATION | |
MX2018008934A (en) | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same. | |
EA201891992A1 (en) | CHIMERIC RECEPTORS AND WAYS OF THEIR APPLICATION | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
PE20171180A1 (en) | ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE | |
MX2019005426A (en) | Anti-lag3 antibodies and antigen-binding fragments. | |
EA201790288A1 (en) | ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, PHARMACEUTICAL COMPOSITION AND APPLICATION | |
MX2023002588A (en) | Anti-tgf-beta antibodies and their use. | |
EA201890145A1 (en) | ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | |
EA201890443A1 (en) | BISPECIFIC MONOVALENT DIATELS, ABLE TO CONNECT B7-H3 AND CD3 AND THEIR APPLICATION | |
EA201790248A1 (en) | MEDIA-ANTIBODY COMPOSITIONS AND METHODS FOR THEIR RECEIVING AND APPLICATION | |
PE20161390A1 (en) | MULTI-SPECIFIC ANTIBODIES | |
EA201692394A1 (en) | ANTIBODIES AND ANTIGENS-BINDING FRAGMENTS, WHICH SPECIFICALLY CONNECT WITH THE PROUCH OF TAU ASSOCIATED WITH MICROTUBULES | |
EA202190609A1 (en) | ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G | |
EA202091130A1 (en) | LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN | |
EA201791590A1 (en) | ANTIBODIES TO TAU AND THEIR APPLICATION | |
EA201691541A1 (en) | NEW ANTI-BAFF ANTIBODIES | |
EA201892716A1 (en) | Antibody to Coagulation Factor XI | |
EA202191785A1 (en) | ANTIBODIES TO CTLA4 AND METHODS OF THEIR APPLICATION | |
EA201992460A1 (en) | BTLA ANTIBODY ANTIBODIES AND THEIR APPLICATION | |
EA201691521A1 (en) | ANTIBODIES TO INTERLEUKIN-21 |